/ CORRECTION - PharmaCom BioVet, Inc.
October 23 2008 - 7:49PM
Marketwired
In the news release, "PharmaCom BioVet, Inc. and IsoTherapeutics
Group, LLC Announces Liquid Brachytherapy Planned for Canine Cancer
Treatment Centers," issued Tuesday, October 21, 2008 by PharmaCom
BioVet, Inc. (PINKSHEETS: PHMB), we are advised by the company that
the headline should read "PharmaCom BioVet, Inc. Announces Direct
Injection Liquid Brachytherapy Planned For Their Canine Cancer
Treatment Centers" rather than "PharmaCom BioVet, Inc. and
IsoTherapeutics Group, LLC Announces Liquid Brachytherapy Planned
for Canine Cancer Treatment Centers" as originally issued. We are
also advised that the first sentence of the first paragraph should
read "PharmaCom Biovet, Inc. is pleased to announce its plans to
explore the ground-breaking Liquid Brachytherapy system for the
direct injection of therapeutic radioisotopes* for use within its
Canine Cancer Treatment Centers." rather than "PharmaCom Biovet,
Inc. is pleased to announce its plans with IsoTherapeutics Group,
LLC to explore the latest ground-breaking direct injection liquid
brachytherapy therapeutic radioisotope procedures* for use within
its canine cancer treatment centers." as originally issued.
Additionally, a paragraph has been added after the fourth
paragraph, and minor revisions have been made throughout the
release. Complete corrected text follows.
PharmaCom BioVet, Inc. Announces Direct Injection Liquid
Brachytherapy Planned For Their Canine Cancer Treatment Centers
RALEIGH, NC -- October 21, 2008 - PharmaCom BioVet, Inc.
(PINKSHEETS: PHMB). PharmaCom BioVet, Inc. is pleased to announce
its plans to explore the ground-breaking Liquid Brachytherapy
System for the direct injection of therapeutic radioisotopes* for
use within its Canine Cancer Treatment Centers.
As part of its plans for state-of-the-art treatment centers for
canine lymphoma and other forms of cancer, PharmaCom BioVet, Inc.
is greatly encouraged by the latest research results in direct
injection of Liquid Brachytherapy radioisotopes into tumors.
Recently published collaborative studies in laboratory mice and
rats and early clinical success in canines by IsoTherapeutics
Group, LLC in Angleton Texas and Valco Instruments Co. Inc. of
Houston* demonstrate that these direct injection procedures are
superior to previous methods in producing increased efficacy in
test cases. These studies have concluded that direct administration
of beta-emitting isotopes into tumorous tissues with an easy to
prepare, proprietary formulation allows for better targeting of the
radioisotope treatment with little to no migration into other
non-cancerous tissues.
Recent advances in cancer treatments such as these are
fundamental to the scientific basis for PharmaCom BioVet, Inc.
"Part of our commitment is to support and harness these
cutting-edge methodologies for both cancer treatment and cancer
prevention," asserts Gary S. Berthold, President and CEO of
PharmaCom BioVet, Inc. "The meaningful research with Liquid
Brachytherapy direct injections provides new hope for companion
animal lovers and adds to the substantive portfolio of treatment
options within our new cancer treatment centers," Berthold
added.
Berthold also stated, "While researching treatments for our own
pets, we discovered a dynamic convergence within the veterinary and
cancer research industries towards providing new treatment
technologies for companion animals suffering from cancer. We also
discovered a large and growing demand for companion animal cancer
care. At the same time we found that there are almost no facilities
dedicated to developing and providing these new treatment programs.
Based on these factors, we decided to dedicate our lives to
creating canine cancer treatments centers around the country," Gary
concluded.
PharmaCom BioVet seeks to further the opportunities available to
people who have encountered cancer in their companion animals and
to offer their animals a better quality of life and longevity. In
response to demand and the current lack of adequate cancer
treatment options and facilities for animal lovers whose pets are
suffering from cancer, PharmaCom BioVet intends to open a network
of companion animal cancer care centers throughout North
America.
About PharmaCom BioVet, Inc.:
PharmaCom BioVet, Inc. is dedicated to advancing the Veterinary
care industry for companion animals by establishing
state-of-the-art treatment centers for lymphoma and other forms of
cancer throughout the country. The purpose of these centers is to
help prolong the quality of life for companion animals with cancer
and pursue the potential for complete cure. These centers will also
operate under the philosophy of providing a compassionate care
environment for both companion animal patients and their owners.
For more information, please visit our website
www.PharmaComBioVet.com.
About IsoTherapeutics Group, LLC:
The mission of IsoTherapeutics Group, LLC is to develop novel
diagnostic and therapeutic agents for the treatment of severe
diseases. ITG both develops their our own technologies as well as
partners with other companies to help develop pharmaceuticals. Of
special interest are radiopharmaceuticals for oncology. In house
expertise includes synthetic organic chemistry, chelation
chemistry, radiochemistry, diagnostic and therapeutic isotopes,
conjugation chemistry, pharmacokinetics, and small animal research
models. For more information, please visit our website
www.isotherapeutics.com.
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements that are subject to risk and uncertainties, including,
but not limited to, the impact of competitive products, product
demand, market acceptance risks, fluctuations in operating results,
political risk and other risks detailed from time to time in
PharmaCom BioVet, Inc.'s filings with the Securities and Exchange
Commission. These risks could cause PharmaCom BioVet, Inc.'s actual
results to differ materially from those expressed in any
forward-looking statements made by, or on behalf of, PharmaCom
BioVet, Inc.
*Reference: Jim Simon, Kenneth McMillan, Keith Frank of
IsoTherapeutics Group LLC, Angleton, Texas. Stan Stearns, Max Loy
of Valco Instruments Co. Inc., Houston, Texas
Contact: Market Ideas, Inc. 877-295-3981 ext. 2
info@marketideasinc.com
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From Apr 2024 to May 2024
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From May 2023 to May 2024